Naotaifang extract treatment results in increased ferroportin expression in the hippocampus of rats subjected to cerebral ischemia Corrigendum in /10.3892/mmr.2015.4630

Liao,Jun; Xia,Xing; Wang,Guo‑Zuo; Shi,Yong‑Mei; Ge,Jin‑Wen

doi:10.3892/mmr.2015.3309

Naotaifang extract treatment results in increased ferroportin expression in the hippocampus of rats subjected to cerebral ischemia

Corrigendum in: /10.3892/mmr.2015.4630

Authors:
- Jun Liao
- Xing Xia
- Guo‑Zuo Wang
- Yong‑Mei Shi
- Jin‑Wen Ge
View Affiliations

Affiliations: Department of Anatomy, Hunan University of Chinese Medicine, Changsha, Hunan 410208, P.R. China, Campus Network Center, Hunan University of Chinese Medicine, Changsha, Hunan 410208, P.R. China, College of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan 410208, P.R. China
Published online on: February 6, 2015 https://doi.org/10.3892/mmr.2015.3309
Pages: 4047-4052
Copyright: © Liao et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression of Ferroportin (Fpn) was examined at different time points in rats following focal cerebral ischemia treated with or without the traditional Chinese medicine Naotaifang. Initially, rats were randomly divided into 2, 6, 12, 24 and 72 h groups following middle cerebral artery occlusion (MCAO) and the mRNA and protein level of Fpn was detected by immunohistochemistry and reverse transcription polymerase chain reaction (RT‑PCR) at the above time points. Secondly, the rats were randomly divided into five groups as follows: Sham surgery group, model group, low‑dose group (3 g/kg NTE), medium dose group (9 g/kg NTE) and the high‑dose group (27 g/kg NTE). After 3 days of corresponding therapy by intragastric administration once a day, the regional cerebral ischemia model was reproduced by the MCAO suture method. On the third day, the neurological behavior of the rats was analyzed by neurobehavioral assessment. Fpn in the hippocampal CA2 region was measured by immunohistochemistry and the mRNA level of Fpn was detected by RT‑PCR. Expression of Fpn in the hippocampal CA2 region reached a peak 12 h after surgery (P<0.05, compared with the model group). The high‑dose group (27 g/kg NTE) exhibited a lower neurological behavior score (P<0.05) and a higher level of expression of Fpn at the mRNA and protein level compared with the sham surgery group and model group (P<0.05). Dysregulation of intracellular iron balance is possibly a new mechanism underlying cerebral ischemia. NTE can protect the neuronal population in the hippocampal CA2 region by adjusting the expression of Fpn to balance iron levels following cerebral ischemia.

View Figures

View References

1	Chu XP and Xiong ZG: Physiological and pathological functions of acid-sensing ion channels in the central nervous system. Curr Drug Targets. 13:263–271. 2012. View Article : Google Scholar :
2	Xu M and Zhang HL: Death and survival of neuronal and astrocytic cells in ischemic brain injury: a role of autophagy. Acta Pharmacol Sin. 32:1089–1099. 2011. View Article : Google Scholar : PubMed/NCBI
3	Xu F, Gu JH and Qin ZH: Neuronal autophagy in cerebral ischemia. Neurosci Bull. 28:658–666. 2012. View Article : Google Scholar : PubMed/NCBI
4	Olmez I and Ozyurt H: Reactive oxygen species and ischemic cerebrovascular disease. Neurochem Int. 60:208–212. 2012. View Article : Google Scholar
5	Belousov AB: Novel model for the mechanisms of glutamate-dependent excitotoxicity: Role of neuronal gap junctions. Brain Res. 1487:123–130. 2012. View Article : Google Scholar : PubMed/NCBI
6	Giuliani D, Minutoli L, Ottani A, et al: Melanocortins as potential therapeutic agents in severe hypoxic conditions. Front Neuroendocrinol. 33:179–193. 2012. View Article : Google Scholar : PubMed/NCBI
7	Rathnasamy G, Ling EA and Kaur C: Iron and iron regulatory proteins in amoeboid microglial cells are linked to oligodendrocyte death in hypoxic neonatal rat periventricular white matter through production of proinflammatory cytokines and reactive oxygen/nitrogen species. J Neurosci. 31:17982–17995. 2011. View Article : Google Scholar : PubMed/NCBI
8	Gebril OH, Simpson JE, Kirby J, Brayne C and Ince PG: Brain iron dysregulation and the risk of ageing white matter lesions. Neuromolecular Med. 13:289–299. 2011. View Article : Google Scholar : PubMed/NCBI
9	Muñoz P and Humeres A: Iron deficiency on neuronal function. Biometals. 25:825–835. 2012. View Article : Google Scholar : PubMed/NCBI
10	Khan AA and Quigley JG: Heme and FLVCR-related transporter families SLC48 and SLC49. Mol Aspects Med. 34:669–682. 2013. View Article : Google Scholar : PubMed/NCBI
11	Garrick MD and Garrick LM: Cellular iron transport. Biochim Biophys Acta. 1790:309–325. 2009. View Article : Google Scholar : PubMed/NCBI
12	Ferraro S, Mozzi R and Panteghini M: Revaluating serum ferritin as a marker of body iron stores in the traceability era. Clin Chem Lab Med. 50:1911–1916. 2012. View Article : Google Scholar : PubMed/NCBI
13	Vermeulen E and Vermeersch P: Hepcidin as a biomarker for the diagnosis of iron metabolism disorders: a review. Acta Clin Belg. 67:190–197. 2012.PubMed/NCBI
14	Fellman V: GRACILE syndrome-a severe neonatal mitochondrial disorder. Duodecim. 128:1560–1567. 2012.
15	Chu WC, Au WY and Lam WW: MRI of cardiac iron overload. J Magn Reson Imaging. 36:1052–1059. 2012. View Article : Google Scholar : PubMed/NCBI
16	Shander A, Berth U, Betta J and Javidroozi M: Iron overload and toxicity: implications for anesthesiologists. J Clin Anesth. 24:419–425. 2012. View Article : Google Scholar : PubMed/NCBI
17	Elborai Y, Uwumugambi A and Lehmann L: Hematopoietic stem cell transplantation for thalassemia. Immunotherapy. 4:947–956. 2012. View Article : Google Scholar : PubMed/NCBI
18	Valenti L, Dongiovanni P and Fargion S: Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. World J Gastroenterol. 18:3782–3786. 2012. View Article : Google Scholar : PubMed/NCBI
19	González-Ramos R, Defrère S and Devoto L: Nuclear factor-kappaB: a main regulator of inflammation and cell survival in endometriosis pathophysiology. Fertil Steril. 98:520–528. 2012. View Article : Google Scholar
20	Annaloro C, Airaghi L, Saporiti G, Onida F, Cortelezzi A and Deliliers GL: Metabolic syndrome in patients with hematological diseases. Expert Rev Hematol. 5:439–458. 2012. View Article : Google Scholar : PubMed/NCBI
21	Theil EC: Iron homeostasis and nutritional iron deficiency. J Nutr. 141:724S–728S. 2011. View Article : Google Scholar : PubMed/NCBI
22	Chen J and Enns CA: Hereditary hemochromatosis and transferrin receptor 2. Biochim Biophys Acta. 1820:256–263. 2012. View Article : Google Scholar
23	Graham RM, Chua AC, Herbison CE, Olynyk JK and Trinder D: Liver iron transport. World J Gastroenterol. 13:4725–4736. 2007.PubMed/NCBI
24	Kasvosve I: Effect of ferroportin polymorphism on iron homeostasis and infection. Clin Chim Acta. 416:20–25. 2012. View Article : Google Scholar : PubMed/NCBI
25	Zheng W and Monnot AD: Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases. Pharmacol Ther. 133:177–188. 2012. View Article : Google Scholar :
26	Boserup MW, Lichota J, Haile D and Moos T: Heterogenous distribution of ferroportin-containing neurons in mouse brain. Biometals. 24:357–375. 2011. View Article : Google Scholar : PubMed/NCBI
27	Pietrangelo A, Caleffi A and Corradini E: Non-HFE hepatic iron overload. Semin Liver Dis. 31:302–318. 2011. View Article : Google Scholar : PubMed/NCBI
28	Schulz K, Kroner A and David S: Iron efflux from astrocytes plays a role in remyelination. J Neurosci. 32:4841–4847. 2012. View Article : Google Scholar : PubMed/NCBI
29	Urrutia P, Aguirre P, Esparza A, et al: Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells. J Neurochem. 126:541–549. 2013. View Article : Google Scholar : PubMed/NCBI
30	Wang HW, Liou KT, Wang YH, et al: Deciphering the neuroprotective mechanisms of Bu-yang Huan-wu decoction by an integrative neurofunctional and genomic approach in ischemic stroke mice. J Ethnopharmacol. 138:22–33. 2011. View Article : Google Scholar : PubMed/NCBI
31	Loh KP, Qi J, Tan BK, Liu XH, Wei BG and Zhu YZ: Leonurine protects middle cerebral artery occluded rats through antioxidant effect and regulation of mitochondrial function. Stroke. 41:2661–2668. 2010. View Article : Google Scholar : PubMed/NCBI
32	Koh PO: Ferulic acid modulates nitric oxide synthase expression in focal cerebral ischemia. Lab Anim Res. 28:273–278. 2012. View Article : Google Scholar
33	Yunhe H, Jinwen G and Zhanying C: Effect of Naotaifang on TXB 2, 6-Keto-PGF 1α in plasma and TNF-α in serum of patients with cerebral infarction with deficiency of Qi and blood stasis. Chinese Journal of Information on Traditional Chinese Medicine. 4:16–17. 2002.
34	Garcia JH: A reliable method to occlude a middle cerebral in wistar rats. Stroke. 24:14231993.
35	González-Delgado M and Bogousslavsky J: Superficial middle cerebral artery territory infarction. Front Neurol Neurosci. 30:111–114. 2012. View Article : Google Scholar : PubMed/NCBI
36	Longa EZ, Weinstein PR, Carlson S and Cummins R: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 20:84–91. 1989. View Article : Google Scholar : PubMed/NCBI
37	Eisenstein RS: Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr. 20:627–662. 2000. View Article : Google Scholar : PubMed/NCBI
38	Bandyopadhyay U, Das D and Banerjee RK: Reactive oxygen species: oxidative damage and pathogenesis. Curr Sci. 77:658–666. 1999.
39	Jinwen G, Song C and Huibin Z: Effect of naotaifang extract on functional changes of coagulation and fibrinolysis of human umbilical veins endothelial cell induced by recombined human tumor necrosis factor alpha. J Trad Chin Med U Hun. 6:4–6. 2005.
40	Zhang Q, Gao WY, Zhang Y, et al: Protective effects of astragalus extract against intermittent hypoxia-induced hippocampal neurons impairment in rats. Chin Med J (Engl). 126:1551–1554. 2013.
41	Yin YY, Zhu FF and Wu GC: Protective effect of astragalosides on anoxia/reoxygenation injury of hippocampal neuron. Zhongguo Zhong Xi Yi Jie He Za Zhi. 30:1173–1177. 2010.In Chinese.
42	Li SL, Chan SS, Lin G, et al: Simultaneous analysis of seventeen chemical ingredients of Ligusticum chuanxiong by online high performance liquid chromatography-diode array detector-mass spectrometry. Planta Med. 69:445–451. 2003. View Article : Google Scholar : PubMed/NCBI
43	Qiu F, Liu Y, Zhang PB, et al: Effects of ligustrazine on hippocampal dentate gyrus cell proliferation after focal cerebral ischemia in adult rats. Nan Fang Yi Ke Da Xue Xue Bao. 26:1400–1403. 2006.PubMed/NCBI
44	Cheng CY, Su SY, Tang NY, et al: Ferulic acid inhibits nitric oxide-induced apoptosis by enhancing GABA(Bl) receptor expression in transient focal cerebral ischemia in rats. Acta Pharmacol Sin. 31:889–899. 2010. View Article : Google Scholar : PubMed/NCBI
45	He YH, Hao XY, Ge JW, et al: Clinical studies on naotaifang in treating patients with cerebral infarction with deficiency of qi and blood stasis in TCM. J Emerg Trad Chin Med. 10:319–320. 2001.
46	Zhu HB, Chen Y, Tan H and Ge JW: Effects of Naotai recipe extracts on cerebral CD34 expression in rats with focal cerebral ischemia. Trad Chin Drug Res Clin Pharma. 22:141–144. 2011.